MaxCyte Scalable Transfection System

项目总结： 斯克里普斯研究分子筛查中心(SRMSC)正在申请资金，用于购买 Maxcell Expert STX®可伸缩转染仪，以取代已达到 报废服务。MaxCyte是一种电穿孔仪器，能够产生高效的 载体DNA、siRNA、RNAi等的转染，同时保持较高的细胞存活率。 电穿孔利用电脉冲在细胞膜上形成临时孔，通过这些孔 物质可以进入细胞，对所有类型的细胞进行瞬时或稳定的转化。虽然 以脂类和PEI试剂为基础的转染剂足以用于台式小批量生产 研究表明，它们用于大批量转基因变得成本高昂，特别是在高通量情况下 筛选(HTS)需求或广泛的研究项目，需要大型单一 批量转染法以支持更长期的研究需求。目前的MaxCyte STX仪器是 2006年为支持NIH的MPLCN计划而收购，但在使用约15年后，OEM供应商 已决定停止支持(2021年12月31日)，并且将不再出售、租赁、维修、升级 或为该报废仪器提供维护服务。虽然有几家制造商 作为电穿孔仪器，MaxCyte STX是唯一适合SRMSC量级的仪器 运营，专为需要敏捷性来执行微观到宏观范围的细分市场而设计 以支持我们的AUT用户和HTS需求。不足为奇的是，许多综合性HTS 筛选中心(医药和学术)采用电穿孔转染法。高 在基于瞬时细胞的表达系统中，吞吐量筛选(HTS)已成为不可缺少的 探针开发和药物发现工具以及斯克里普斯研究分子筛选中心 (SRMSC)在为斯克里普斯和其他学术机构的NIH调查人员提供服务方面一直走在前列。 自2005年开始运作以来，我们已经筛选了370多个目标，产生了100多个目标 我们在斯克里普斯和其他机构的合作者获得了100万个数据点。超过136篇科学论文 无数的演示展示了我们产生优秀研究驱动数据的能力。我们的 筛选结果导致开发了77多个针对新药的生物活性分子探针 目标包括一些成功地作为IND进入临床试验测试并最终 NDA/FDA药物(例如ZEPOSIA®(又名OzAnimod)。MaxCyte STX将允许SRMSC实现其 目前的HTS筛查义务，并继续为NIH社区提供其 全面的HTS药物发现能力。

PROJECT SUMMARY: The Scripps Research Molecular Screening Center (SRMSC) is requesting funds for the purchase of a MaxCyte ExPERT STx® Scalable Transfection instrument to replace an older unit which has reached end-of-life service. The MaxCyte is an electroporation instrument capable of producing highly efficient transfections of plasmid DNA, siRNA, RNAi and more, while maintaining high cell viability. Electroporation uses electrical pulses to create temporary pores in cell membranes through which substances can pass into cells to create either transient or stable transfections of all cell types. Although lipid and PEI reagent-based transfections are adequate for small batch production as used in bench-top research, their use for large batch transfections becomes cost prohibitive especially for high throughput screening (HTS) needs or extensive research projects that require the consistency of a large single batch transfection to sustain longer term research needs. The current MaxCyte STX instrument was acquired in 2006 in support of NIH's MPLCN program, but after ~15-years of usage, the OEM vendor has decided to discontinue support (December 31, 2021) and will no longer sell, lease, repair, upgrade or provide maintenance to this end-of-life instrument. While there are several manufacturers of electroporation instruments, the MaxCyte STX is uniquely suited to the magnitude of the SRMSC operations and is designed for a niche that requires the agility to perform micro- to macro- scale transfections in support of our AUT users and HTS needs. Not surprisingly, many comprehensive HTS screening centers (both Pharma & academic) employ electroporation transfection systems. High Throughput Screening (HTS) in transient cell-based expression systems has become an indispensable tool for probe development and drug discovery and the Scripps Research Molecular Screening Center (SRMSC) has been in the forefront in serving NIH investigators at Scripps and other academic institutes. Since establishing operations in 2005, we have screened over 370 targets to generate more than 100 million data points for our collaborators at Scripps and at other institutions. Over 136 scientific papers and numerous presentations demonstrate our ability to produce excellent research-driven data. Our screening results have led to the development of over 77 bioactive molecular probes against novel drug targets including some that have successfully advanced as INDs for clinical trial testing and eventually NDA/FDA drugs (e.g., ZEPOSIA® (a.k.a. ozanimod). The MaxCyte STX will allow SRMSC to fulfill its current HTS screening obligations and continue to serve the NIH community at large with its comprehensive HTS drug discovery capabilities.